AKT1 and neoplasm: p53 mutations might interact with other oncogenic pathways (like PI3K/AKT and MAPK), further supporting tumor progression and resistance to therapy [102], and may also influence the tumor microenvironment through immune regulatory pathways, potentially enabling tumors to evade immune surveillance [103].